II. Indications
- Neuroblastoma
- Melanoma (experimental)
III. Mechanism
- Ganglioside GD2
- GD2 is the cell surface receptor Glycolipid disialoganglioside
- GD2 functions as a part of development and differentiation pathways
- GD2 is expressed on all tumors of neuroectodermal origin
- Includes Melanoma, Neuroblastoma, Sarcoma, astrocytoma, Small Cell Lung Cancer
- GD2 is the cell surface receptor Glycolipid disialoganglioside
- GD2 Monoclonal Antibody (e.g. Dinutuximab)
- Chimeric mouse-human Monoclonal Antibody that binds cells expressing GD2 on their surface
- Antibody binding induces cytotoxicity (complement and Cell-mediated)
IV. Dosing
- See other references for disease specific dosing protocols
V. Adverse Effects
- Infusion Reaction
- Neurologic
- Severe neuropathic pain
- Transverse Myelitis
- Vision changes
- Electrolyte abnormalities
- Cytopenia
- Cardiovascular
- Hypotension
- Capillary leak syndrome
- Other common adverse effects
- Elevated Liver Function Tests
- Urticaria
- Fever
VI. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, Pregnancy category X)
- Use reliable Contraception
- Monitoring
- Complete Blood Count with differential and Platelet Count
- Serum Electrolytes (including Sodium, Potassium, Calcium)
- Liver Function Tests